The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): A concurrent microdialysis and plasma analysis study

Hormones and Behavior

Volumn 61, Issue 2, 2012, Pages 181-190

  Murnane, K S ^a   Kimmel, H L ^a,b   Rice, K C ^c   Howell, L L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Fluoxetine; M100907; MDMA; Prolactin; Rhesus; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUOXETINE; PROLACTIN; SEROTONIN; VOLINANSERIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; ENZYME REGULATION; ENZYME RELEASE; FEMALE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STEREOISOMERISM;

ANIMALS; FEMALE; FLUOROBENZENES; FLUOXETINE; HALLUCINOGENS; MACACA MULATTA; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERIDINES; PROLACTIN; SEROTONIN AGENTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; TIME FACTORS;

EID: 84856970684     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2011.10.012     Document Type: Article

References (45)

1. Aloi J.A., Insel T.R., Mueller E.A., Murphy D.L. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci. 1984, 34(14):1325-1331.
2. Aulakh C.S., Mazzola-Pomietto P., Hill J.L., Murphy D.L. Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J. Pharmacol. Exp. Ther. 1994, 271(1):143-148.
3. Baker L.E., Broadbent J., Michael E.K., Matthews P.K., Metosh C.A., Saunders R.B., et al. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav. Pharmacol. 1995, 6(3):263-275.
4. Banks M.L., Andersen M.L., Murnane K.S., Meyer R.C., Howell L.L. Behavioral and neurochemical effects of cocaine and diphenhydramine combinations in rhesus monkeys. Psychopharmacology 2009, 205(3):467-474.
5. Banks M.L., Sprague J.E., Czoty P.W., Nader M.A. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology 2008, 196(1):63-70.
6. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149(1-2):159-163.
7. Baumann M.H., Clark R.D., Franken F.H., Rutter J.J., Rothman R.B. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 2008, 152(3):773-784.
8. Berger U.V., Gu X.F., Azmitia E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 1992, 215(2-3):153-160.
9. Biezonski D.K., Courtemanche A.B., Hong S.B., Piper B.J., Meyer J.S. Repeated adolescent MDMA ("Ecstasy") exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist. Brain Res. 2009, 1252:87-93.
10. Bubar M.J., Pack K.M., Frankel P.S., Cunningham K.A. Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 2004, 173(3-4):326-336.
11. Cole J.C., Bailey M., Sumnall H.R., Wagstaff G.F., King L.A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002, 97(12):1531-1536.
12. Cowen P.J., Sargent P.A. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J. Psychopharmacol. 1997, 11(4):345-348.
13. Czoty P.W., Justice J.B., Howell L.L. Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys. Psychopharmacology 2000, 148(3):299-306.
14. Dumont G.J., Sweep F.C., van der Steen R., Hermsen R., Donders A.R., Touw D.J., et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci. 2009, 4(4):359-366.
15. Emiliano A.B., Fudge J.L. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004, 29(5):833-846.
16. Fantegrossi W.E., Bauzo R.M., Manvich D.M., Morales J.C., Votaw J.R., Goodman M.M., et al. Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology 2009, 205(2):337-347.
17. Fantegrossi W.E., Godlewski T., Karabenick R.L., Stephens J.M., Ullrich T., Rice K.C., et al. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 2003, 166(3):202-211.
18. Fantegrossi W.E., Kiessel C.L., De la Garza R., Woods J.H. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology 2005, 181(3):529-536.
19. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 2002, 161(4):356-364.
20. Fleckenstein A.E., Volz T.J., et al. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
21. Glennon R.A., Yousif M., Patrick G. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol. Biochem. Behav. 1988, 29(3):443-449.
22. Gough B., Ali S.F., Slikker W., Holson R.R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 1991, 39(3):619-623.
23. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55(3):463-508.
24. Gudelsky G.A., Nash J.F. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 1996, 66(1):243-249.
25. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162(4):396-405.
26. Hatzidimitriou G., Tsai E.H., McCann U.D., Ricaurte G.A. Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine. Synapse 2002, 44(1):51-57.
27. Kimmel H.L., O'Connor J.A., Carroll F.I., Howell L.L. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol. Biochem. Behav. 2007, 86(1):45-54.
28. Kristiansen H., Elfving B., Plenge P., Pinborg L.H., Gillings N., Knudsen G.M. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse 2005, 58(4):249-257.
29. Liechti M.E., Baumann C., Gamma A., Vollenweider F.X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000, 22(5):513-521.
30. Liechti M.E., Vollenweider F.X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 2001, 16(8):589-598.
31. McClung J., Fantegrossi W., Howell L.L. Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology 2010, 210(1):75-83.
32. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br. J. Pharmacol. 2002, 135(1):170-180.
33. Meltzer H.Y., Maes M. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men. Psychiatry Res. 1995, 58(2):89-98.
34. Mook D., Felger J., Graves F., Wallen K., Wilson M.E. Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques. Psychoneuroendocrinology 2005, 30(3):273-283.
35. Muller E.E., Locatelli V., Cella S., Penalva A., Novelli A., Cocchi D. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 1983, 25(4):399-432.
36. Murnane K.S., Fantegrossi W.E., Godfrey J.R., Banks M.L., Howell L.L. Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J. Pharmacol. Exp. Ther. 2010, 334(2):642-650.
37. Murnane K.S., Murai N., Howell L.L., Fantegrossi W.E. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. J. Pharmacol. Exp. Ther. 2009, 331(2):717-723.
38. Nash J.F., Roth B.L., Brodkin J.D., Nichols D.E., Gudelsky G.A. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci. Lett. 1994, 177(1-2):111-115.
39. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs 1986, 18(4):305-313.
40. Spigset O., Mjorndal T. The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. J. Clin. Psychopharmacol. 1997, 17(4):292-297.
41. Stein D.J., Rink J. Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. J. Clin. Psychiatry 1999, 60(7):485.
42. Sulzer D., Sonders M.S., et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75(6):406-433.
43. Wilcox K.M., Kimmel H.L., Lindsey K.P., Votaw J.R., Goodman M.M., Howell L.L. In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse 2005, 58(4):220-228.
44. Wilcox K.M., Lindsey K.P., Votaw J.R., Goodman M.M., Martarello L., Carroll F.I., et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 2002, 43(1):78-85.
45. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 1995, 273(3):1063-1070.